Clinical Trials Logo

Filter by:
NCT ID: NCT03667690 Completed - Fungal Infection Clinical Trials

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

ReSTORE
Start date: October 7, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by optional oral fluconazole).

NCT ID: NCT03666208 Completed - Clinical trials for End Stage Renal Failure on Dialysis

Sirolimus Coated Angioplasty Balloon in the Salvage of Thrombosed Arteriovenous Graft

Start date: July 1, 2018
Phase: Phase 2
Study type: Interventional

End stage renal disease is on increasing trend. Haemodialysis is the main dialysis modality among these patients which accounts for the incidence of 81.3% in 2015 based on data from Singapore renal registry. Thus, A functioning dialysis vascular access (either arteriovenous Fistula or graft) is critical to the delivery of life-saving haemodialysis treatment to these patients. The main focus in our study is thrombosed (blocked) AVG as it has higher thrombosis rate and poorer patency rate. Conventionally, to restore the function of the dialysis access, the thrombus (clot) will be lysed with the use of lytic agent; followed by treatment of the underlying stenosis (narrowing) with plain balloon angioplasty (dilatation). However narrowing often recur and multiple repeated angioplasty procedures are needed keep the AVG flowing to prevent clots formation. Recently developed balloons called drug eluting balloons, are coated with medications to prevent the narrowing from recurring after angioplasty. With these drug balloons, the AVG can potentially continue to have good flow for a longer period of time, hence, decreasing the chance of clotting. A newer generation of drug-eluting balloon, called sirolimus coated balloon, are coated with a medicine called sirolimus. It has been successfully used in the treatment of narrowing of vessels in the leg and heart and it were superior than conventional paclitaxel coated balloon angioplasty. We hypothesis that sirolimus coated balloon is superior to conventional plain balloon angioplasty with decreased re-stenosis of target lesion, improved access circuit and target lesion patency, and decreased number of interventions needed to maintain patency.

NCT ID: NCT03665961 Completed - Central Obesity Clinical Trials

The Association Between Microbiota, Endotoxaemia and the Host Obesity/ Insulin Resistance (MiPOOP Study)

MiPOOP
Start date: October 25, 2016
Phase:
Study type: Observational

The objectives of this study are to examine the effects of ethnicity, central obesity and dietary components, on the human gut microbiome. The investigators hypothesize that these factors have an influence on the composition of the gut microbiome. Healthy subjects (n=35) provided stool samples for gut microbiome profiling using 16S rRNA sequencing and completed a dietary questionnaire. The serum samples were assayed for a panel of inflammatory cytokines. Their associations with central obesity were examined.

NCT ID: NCT03663296 Completed - Education, Medical Clinical Trials

Assessing Usefulness of Virtual Reality Mobile Application in Flexible Videoscope Airway Training

AURA
Start date: July 24, 2018
Phase: N/A
Study type: Interventional

Flexible videoscope orotracheal intubation (FOI) technique is considered an important option in the management of predicted difficult airways. However, it is rarely performed in daily practice. Yet emergency physicians are expected to be able to perform this skill expertly during a crisis scenario. If it is not completed in a timely and proper fashion, the patient will deteriorate rapidly, resulting in morbidity or fatality. There is a significant learning curve to master this complex psychomotor skill. Providing sufficient training in FOI, particularly hands-on experience in real patients is difficult. Patients with known difficult airway requiring FOI present infrequently to the emergency room. Using patients with normal airway purely for teaching of FOI is ethically controversial. To avoid technical and ethical concerns of training involving real patients, conventional teaching methods incorporate the use of a low-fidelity manikin in replacement. However, the manikin anatomy often lacks the realism of a live human. The addition of virtual reality technology, in the form of a low-cost mobile application (Airway Ex) into the conventional simulation, may optimize learning by providing an ethical, cost-effective and more realistic modality to acquire the basic skills of FOI. If it is proven to be effective, efforts to integrate virtual reality technology into routine training of such procedures in the ED should be promoted. We hypothesize that the addition of virtual reality mobile application to conventional training will improve procedural skill dexterity and proficiency and hence, improve learner's satisfaction and confidence in performing FOI.

NCT ID: NCT03662659 Completed - Gastric Cancer Clinical Trials

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Start date: October 16, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of investigational drug relatlimab plus nivolumab in combination with chemotherapy in participants with unresectable, untreated, locally advanced or metastatic gastric or GEJ cancer.

NCT ID: NCT03661606 Completed - Healthy Clinical Trials

Biovitals Analytics Engine - Altitude Study

Start date: July 30, 2018
Phase: N/A
Study type: Interventional

Unexpected adverse health events resulting in a hospital admission can be potentially avoided by leveraging novel physiological sensors combined with advanced computational techniques to predict changes in physiology prior to the onset of symptoms. In other words, significant improvement in the prevention of avoidable hospitalization can be achieved via early detection and actionable insights of clinical deterioration at the individual patient level as they go about their normal day to day activities. Physiological changes can be a warning sign that a person's health is deteriorating and as such is an important component of an early detection tool. The Biovitals Analytics Engine (BA Engine) is intended to be used with data from already validated sensors measuring physiological parameters, including heart rate (HR), respiratory rate (RR) and activity in ambulatory patients being monitored in a healthcare facility or at home. The device provides a continuous output- Biovitals™ Index (BI) which indicates whether the relationships among the patients monitored vital signs change from those measured at baseline (derived from measurements previously obtained during daily routine activities). The BI is based on an integrated computation evaluating changes in the parameters and their relationship to each other. As part of the clinical validation of the BA Engine, it is important to first undertake an analytical validation to demonstrate that the BA correctly processes the physiological data for which it is designed, and generates an accurate detection of physiological change. In order to generate a measurable physiological change, subjects will move from sea level to an altitude environment which is known to cause increases in HR and RR.

NCT ID: NCT03659409 Completed - Stroke Clinical Trials

Stroke Of Mindfulness: Investigating Physiological and Psychological Well-being

SOM
Start date: May 12, 2016
Phase: N/A
Study type: Interventional

This study evaluates the impact of mindfulness-based interventions on psycho-social and physiological well-being among stroke survivors and their family caregivers. This study will employ a treatment wait-list cross-over design, with half the participants randomized to receive the intervention first (treatment group), while the other half receives the interventions 2 months following the end of the treatment phase (wait-list group).

NCT ID: NCT03658252 Completed - Clinical trials for Adherence, Medication

Efficacy of Targeted Intervention for Topical Steroid Phobia.

Start date: October 1, 2018
Phase: N/A
Study type: Interventional

Topical steroids are an important component of treatment for many dermatological conditions, however 'Corticosteroid phobia' is a significant factor contributing to non adherence to prescribed therapy. The primary aim of this study is to determine the effectiveness of targeted education, and involvement in a moderated social forum in reducing steroid phobia as assessed by the TOPICOP© score. Secondary objectives include determining if a decrease in TOPICOP© score correlates to an increase in compliance, or an improvement in quality of life.

NCT ID: NCT03657225 Completed - Acute Kidney Injury Clinical Trials

Mini Versus Conventional Cardiopulmonary Bypass In CABG in Asian Patients

MiniCPB
Start date: November 2008
Phase: N/A
Study type: Interventional

Our intention is to perform a randomized controlled trial to compare the efficacy and safety of mini cardiopulmonary bypass system to a modified conventional bypass circuit in 80 Asian patients undergoing elective CABG. Our intend is to confirm the efficacy of mini-bypass in reducing haemodilution and reducing blood transfusions, and investigate if this is associated with reduced inflammation and better cardiovascular, neurological, renal, respiratory and infection outcome.

NCT ID: NCT03657160 Completed - Clinical trials for Hematopoietic Stem Cells

Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

Start date: February 6, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder.